A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-Line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung.

Trial Profile

A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-Line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms First-SIGNAL
  • Most Recent Events

    • 27 Feb 2012 Results published in the Journal of Clinical Oncology.
    • 30 Mar 2010 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top